Loading
Everything OnCo dates to 2000: 82 entries, 25 landmarks, 13 companies founded, 11 papers and 11 papers listed on people's pages. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
82 dated entries in OnCo fall in 2000: 25 landmarks, 13 companies founded, 11 papers, 11 papers listed on people's pages, 8 journals founded, 7 technologies, 5 approvals, 1 law or regulation and 1 regulatory event.
Of those, 1 to the day and 81 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Relapsed/refractory APL
Oncology: assessment of abnormal glucose metabolism to assist in evaluating malignancy
Relapsed CD33+ AML (withdrawn 2010)
Thyroglobulin testing and radioiodine imaging in thyroid cancer follow-up; pre-therapeutic stimulation for radioiodine ablation
Palliative treatment of advanced prostate cancer
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
Accelerated approval, relapsed CD33+ AML in older patients; first ADC ever approved
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
European Union, regulation.
The publication year on key paper records.
Swanson KR, Alvord EC, Murray JD. Cell proliferation.
van der Zee J, González González D, van Rhoon GC, et al. The Lancet.
Alizadeh AA, Eisen MB, Davis RE, et al. Nature.
Górski B, Byrski T, Huzarski T, et al. American Journal of Human Genetics.
Gotoda T, Yanagisawa A, Sasako M, et al. Gastric cancer.
Perou CM, Sørlie T, Eisen MB, et al. Nature.
Peto R, Darby S, Deo H, et al. BMJ.
Stojdl DF, Lichty B, Knowles S, et al. Nature Medicine.
Hanahan D, Weinberg RA. Cell.
Therasse P, Arbuck SG, Eisenhauer EA, et al. JNCI: Journal of the National Cancer Institute.
Vogelstein B, Lane D, Levine AJ. Nature.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Acute promyelocytic leukaemia
Hodgkin lymphoma
Rare cancers of childhood (NCI PDQ umbrella). Creates a registry and protocols for infrequent tumours.
Head and neck squamous cell carcinoma. Meta-analysis (MACH-NC) confirms ~6.5% absolute survival gain.
Chronic lymphocytic leukaemia. del(17p) and del(11q) adverse; del(13q) favourable.
Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma). Series from Pittsburgh and Europe show equivalence to open surgery.
Early gastric cancer
Gestational trophoblastic neoplasia
Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)
High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)
Neuroendocrine tumours
Acute myeloid leukaemia. Accelerated approval in relapsed CD33+ AML; withdrawn 2010 after SWOG S0106 toxicity.
Acute myeloid leukaemia
Diffuse large B-cell lymphoma
HPV-positive oropharyngeal cancer
Oropharyngeal cancer (tonsil and base of tongue). Gillison and colleagues show HPV16 in a distinct subset of tumours.
Acute lymphoblastic leukaemia. First BCR::ABL1 inhibitor; Ph+ ALL survival doubles when added to chemotherapy.
Gastrointestinal stromal tumour (GIST)
Colorectal cancer. FOLFIRI and FOLFOX double median metastatic survival from ~12 to ~20 months.
Triple-negative breast cancer (TNBC). Perou and Sørlie's expression profiling separates basal-like from luminal breast cancers.
Breast cancer (all types). Perou and Sorlie's expression profiling defines luminal, HER2-enriched and basal-like breast cancers.
Follicular thyroid cancer
Post-transplant lymphoproliferative disorder (PTLD). Case series and the French multicentre trial (Blood 2006) establish anti-CD20 therapy.
Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)
Pheochromocytoma and paraganglioma (PPGL). Baysal and colleagues, Science: metabolic enzyme genes as tumour suppressors.
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Bothell, WA
Bengaluru
Monrovia, CA
Cambridge, MA
Hong Kong / Shanghai
Ulaanbaatar
Halifax, Nova Scotia
Menlo Park, CA
New York, NY
Cambridge, MA
Tampere
Osaka
Shanghai
The founded year on journal records.
Asian Pacific Organization for Cancer Prevention (APOCP), hosted by the West Asia Organization for Cancer Prevention
BMC (Springer Nature)
Korean Cancer Association
Elsevier
Springer
Springer
Wolters Kluwer (Lippincott Williams & Wilkins)
Elsevier
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Nature
Cerebrovasc Dis
Journal of Infectious Diseases
Oncogene
New England Journal of Medicine
Journal of Experimental Medicine
Nature Medicine
Urologia Internationalis
JCO
American Journal of Clinical Nutrition
Genetic Testing